Clinical Trial

Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)

Study acronym: RAPID-I
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the effectiveness and safety of infliximab in the treatment of acute pancreatitis in adults. A third of participants will receive one single dose of infliximab via infusion, another third will receive a higher dose of infliximab via infusion and the final third of participants will receive a placebo infusion.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-09-24; most recent amendment 2026-07-01.
Status change: Suspended → Recruiting 2022-03-01
Status change: Recruiting → Suspended 2020-11-02
Status change: Not Yet Recruiting → Recruiting 2019-07-02
Trial Details
NCT Number NCT03684278
Lead Sponsor University of Liverpool
Collaborators: Bangor University, Liverpool University Hospitals NHS Foundation Trust, Medical Research Council, National Institute for Health Research, United Kingdom, Merck Sharp & Dohme LLC
Conditions Acute Pancreatitis
Enrollment 240 participants
Start Date 2019-05-01
Primary Completion 2026-12-15 (estimated)
Study Completion 2027-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-06